Oxurion

Oxurion, founded in 1997 and listed on Euronext Brussels, is a biotech company in a significant strategic transition. Its core mission remains the development of novel therapies for serious retinal diseases to prevent blindness. However, its current and actively executed strategy is to build a diversified service group by acquiring majority stakes in pharmaceutical subcontractors, starting with a 72% stake in Axiodis CRO, aiming for more stable revenue streams alongside its R&D efforts.

No proprietary technology platform detailed in current materials; historical focus was on small molecule drug discovery.

In therapeutics, it is not an active competitor in the crowded GA/AMD space. In services, it competes as a nascent consolidator against global CRO giants and numerous regional players, aiming to compete on integrated niche expertise rather than scale.